{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:32Z","timestamp":1791612452218,"version":"4.3.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review recent evidence for infection rates in patients with systemic vasculitides, the role of specific infectious agents in the pathogenesis of vasculitis and recent breakthroughs in the treatment of virus-associated vasculitides.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In well designed recent studies, infections were found to be common during the first 6\u201312 months in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) and giant cell arteritis (GCA) and to contribute significantly to increased mortality during this period. New therapeutic schemes with lower cyclophosphamide doses and shorter corticosteroid courses were associated with decreased infectious rates in elderly patients with AAV whereas a prednisone dose greater than 10\u200amg\/day at the end of the first year were associated with increased infectious-related mortality in patients with GCA. Recently, a potential role for varicella zoster virus in GCA pathogenesis has been proposed but more data are needed in order to establish a causal relationship. Finally, preliminary data show excellent short-term efficacy and safety of the new, interferon-free, oral antiviral agents in the treatment of hepatitis C virus-associated cryoglobulinemic vasculitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Infections continue to be one of the main causes of mortality in patients with systemic vasculitides, emphasizing the need for safer immunosuppressive therapies and appropriate prophylaxis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000348","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T17:42:10Z","timestamp":1474479730000},"page":"17-23","source":"Crossref","is-referenced-by-count":26,"title":["Infections and vasculitis"],"prefix":"10.1097","volume":"29","author":[{"given":"Konstantinos","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur J Clin Invest"},{"issue":"(Suppl 1)","key":"R3-20230829","doi-asserted-by":"crossref","first-page":"i171","DOI":"10.1093\/ndt\/gfv045","article-title":"Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function","volume":"30","author":"McGregor","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1097\/MD.0000000000000843","article-title":"The CD4 lymphocyte count is a better predictor of overall infection than the total lymphocyte count in ANCA-associated vasculitis under a corticosteroid and cyclophosphamide regimen: a retrospective cohort","volume":"94","author":"Shi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"(Suppl 1)","key":"R8-20230829","doi-asserted-by":"crossref","first-page":"i123","DOI":"10.1093\/ndt\/gfv076","article-title":"Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"30","author":"McGregor","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multisystem autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/acr.22757","article-title":"Association of low B cell count and IgG levels with infection, and poor vaccine response with all-cause mortality in an immunosuppressed vasculitis population","volume":"68","author":"David","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","article-title":"Clinical features of polymyalgia rheumatica and giant cell arteritis","volume":"8","author":"Salvarani","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/acr.22429","article-title":"Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities","volume":"67","author":"Petri","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/art.39596","article-title":"Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study","volume":"68","author":"Schmidt","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"e000137","DOI":"10.1136\/rmdopen-2015-000137","article-title":"Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis","volume":"2","author":"Evans","year":"2016","journal-title":"RMD Open"},{"key":"R18-20230829","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.151252","article-title":"Tocilizumab in giant cell arteritis: a multicentre retrospective study of 34 patients","author":"Regent","year":"2016","journal-title":"J Rheumatol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"589841","DOI":"10.1155\/2015\/589841","article-title":"Development and implementation of a double-blind corticosteroid-tapering regimen for a clinical trial","volume":"2015","author":"Collinson","year":"2015","journal-title":"Int J Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11910-015-0614-5","article-title":"Developments in varicella zoster virus vasculopathy","volume":"16","author":"Nagel","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0000000000000292","article-title":"Varicella zoster virus triggers the immunopathology of giant cell arteritis","volume":"28","author":"Gilden","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1212\/WNL.0000000000001409","article-title":"Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis","volume":"84","author":"Gilden","year":"2015","journal-title":"Neurology"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamaneurol.2015.2101","article-title":"Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis","volume":"72","author":"Nagel","year":"2015","journal-title":"JAMA Neurol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1093\/infdis\/jiw101","article-title":"Varicella zoster virus infection in granulomatous arteritis of the aorta","volume":"213","author":"Gilden","year":"2016","journal-title":"J Infect Dis"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yexmp.2015.12.007","article-title":"VZV, temporal arteritis, and clinical practice: false positive immunohistochemical detection due to antibody cross-reactivity","volume":"100","author":"Pisapia","year":"2016","journal-title":"Exp Mol Pathol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaneurol.2015.0840","article-title":"Successful antiviral treatment of giant cell arteritis and takayasu arteritis","volume":"72","author":"Gilden","year":"2015","journal-title":"JAMA Neurol"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","article-title":"Cryoglobulinemia vasculitis","volume":"128","author":"Cacoub","year":"2015","journal-title":"Am J Med"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11926-015-0526-z","article-title":"HCV treatments and their integration into rheumatology","volume":"17","author":"Vassilopoulos","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"e000008","DOI":"10.1136\/rmdopen-2014-000008","article-title":"For patients with rheumatic disease and hepatitis C infection: the end of interferon","volume":"1","author":"Calabrese","year":"2015","journal-title":"RMD Open"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"R35-20230829","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kew268","article-title":"Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy","author":"Sollima","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"e0154970","DOI":"10.1371\/journal.pone.0154970","article-title":"Epidemiology of hospital admissions with influenza during the 2013\/2014 northern hemisphere influenza season: results from the global influenza hospital surveillance network","volume":"11","author":"Puig-Barbera","year":"2016","journal-title":"PLoS One"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R39-20230829","article-title":"Pneumococcal and influenza vaccination rates in patients treated with corticosteroids and\/or immunosuppressive therapies for systemic autoimmune diseases: a cross-sectional study","author":"Assala","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R40-20230829","article-title":"Vasculitis as an adverse event following immunization -- systematic literature review","author":"Bonetto","year":"2015","journal-title":"Vaccine"},{"key":"R41-20230829","first-page":"89","article-title":"Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study","volume":"34","author":"Kerneis","year":"2016","journal-title":"Clin Exp Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201701000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:39:06Z","timestamp":1693291146000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201701000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000348","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}